Editorial Comment on: Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma
-
Published:2009-07
Issue:1
Volume:56
Page:132-133
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Reference8 articles.
1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007
3. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007
4. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon-2a as first-line therapy in metastatic renal-cell carcinoma;Escudier;J Clin Oncol,2007
5. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma;Doehn;Eur Urol,2009